Background: In France, control of chemotherapy preparations is highly recommended. Analytical control is a method of choice for identifying and quantifying drugs. Pediatric preparations, which often contain small quantities of drugs and are made in low final volumes were until then not analytically controlled. After the development and validation of a new sampling and assaying method for low volume chemotherapy preparations with an UV/Raman automaton (QCPrep + ), the quality control results of the preparations intended for the patients were analyzed over a period of eighteen months Methods: The results were studied by type of preparation (low and high volume), per molecule, manipulator, and conformity rates dispersion. Results: Over the period, 7,548 controls were carried out, representing 87.7% of our production. 75.5% of these controls concerned low-volume preparations ( < 50mL). The overall conformity rate was 94.4%. The lowest conformity rates were found for vinca alkaloids, methotrexate and some rarely manipulated drugs (cisplatin, decitabine, epirubicin). The study of the results dispersion showed non-conformities increasing with low concentrations, specific to pediatrics. These results show the limits of analytical control for pediatric preparations. The low analytical sensitivity encountered for certain concentrations and drugs requires a complementary quality control tool, like camera or video. However this new analytical method allows us to improve the safety of the injectable chemotherapy circuit.
Introduction
Securing the injectable cytotoxic drugs preparation circuit is part of the hospital pharmacist's priorities [1] [2] [3] . The French National Agency of Drug Safety (ANSM) classifies cytotoxic drug overdose in pediatrics among the twelve events that should never happen ("never events") [4] . The various quality controls put in place are designed to ensure that the patient receives the expected chemotherapy: right drug, at the right dose and in the right solvent [5, 6] . Whatever the chosen methods, it requires investments in time, equipment and personnel [7] . The analytical control is an alternative to the gravimetric methods [8] and to visual inspection (by the staff or with camera [9] ). The French Society of Oncology Pharmacy (SFPO) recommends, keeping account of technological advances, to establish, as a priority, this method in the quality assurance policy [10] . The main advantages of analytical control are the information delivered: the identification of the drug and solvent and the quantification of the drug are provided [11] . Analytical controls of chemotherapies have few specificities. On analytical perspective, these preparations have a very simple composition: a single substance in a solvent, at high concentrations (on the order of g/L). From an organizational point of view, preparations are made for a single patient at the same day (or potentially the day before). The control must be fast and able to fit into the workflow. Several techniques exist: high performance liquid chromatography coupled with an UV-Visible detector (HPLC-UV) is a technique widely used in the field of analytical control and is considered, by some authors, as the gold standard for the control of chemotherapy preparations [6] . However, this method has some inconvenient like technical and time constraints which can be a limiting factor for the integration of an analytical control in real time. Other techniques were developed to allow faster controls: high-performance thin layer chromatography (HPTLC) [12] , automaton coupling ultraviolet (UV) and Fourier-Transformed Infrared spectroscopy (UV/vis-FTIR) (Multispec ® ) [13, 14] or Raman spectroscopy (UV-Raman) (QCPrep ® ) [15] [16] [17] [18] . HPTLC concept is interesting because it allows significant time savings by successfully analyzing more than 20 samples in one run. Automatons (Multispec ® and QCPrep ® ) are widely used and have some advantages: direct analysis without chromatography, reduction of the analysis time (less than 2 minutes); the combination of UV, IR or Raman spectroscopy provides enough information to identify and discriminate some structurally related molecules from the spectra and identify the solvent [6] . The main limitation is the large volume required for analysis (1.2 ml) although it can be decreased to 1 ml [15] .
The specificity of pediatric oncology lies in the prescribed doses and the preparation volumes which are lower than in adults, therefore the range of concentrations is very wide. In practice, the majority of preparations are made in syringes with a final volume of less than 50 ml. The analysis, destructive, required to carry a sampling which then generates several problems: a discrepancy between the final volume and the labeling, an important fraction of the total dose used for the control and low concentrations can cause analytical sensitivity problems. These preparations are usually not analytically controlled.
After acquiring a QCPrep+ ® automaton, we have developed and validated a new method for the control of low volume preparations, in syringe or infusion bag, with a final volume of 20 to 50 ml [15] . This method is based on an overfilling of the preparation with 1 ml of solvent, a sample volume of 1 ml and an analysis volume of 900 µL. This method is also used for the control of high volume preparations, but without overfilling (1 ml of sample was directly withdrawn). We report daily controls results of preparations destined to patients, obtained during 18 months after the validation of our method. The main objective is to improve the safety of children treated with anticancer chemotherapy and to improve our practices by evaluating the conformity rates obtained with the analytical control. The origin of non-conformities (NC) was also analyzed.
Materials and methods

Equipment
The QCPrep+ ® analyzer is an "all in one" automaton composed of a sampling and injection system, a spectrometric analysis system and two management software's. Sample vials are placed on a motorized carousel with 110 slots coupled to a rotatable turret performing sampling and injections. This turret is composed of a 2.5 ml syringe with a micrometer screw (accuracy of 0.1% v/v), and a needle able to penetrate the septum. Unlike the Multispec ® analyzer, the QCPrep+ ® is able to dilute the samples and the analysis volumes can be modified. The analysis system consists in a spectrophotometer and a RAMAN spectrometer (BWTek ® (USA)). Each spectrometer is equipped with a sample cell: the UV cell is first filled with 500 μL of sample before the Raman cell. If the sample volume is less than 1 ml, the UV cell is completely filled while Raman cell is partially filled and the quality of the analysis is poor. In most cases, UV analysis is sufficient to identify and quantify the drugs. For drugs with close molecular conformations, such as anthracyclins or oxazophosphorins, Raman analysis is necessary to discriminate them. Identification is performed by comparing the acquired spectra with prerecorded ones. After identification, quantification is carried out from the drug calibration curve. One analysis is performed in less than 2 minutes. The calibration curves are plotted automatically by the QCPrep + ® through its ability to perform dilutions.
Thus, for each drug, only the highest point of the range was prepared and further automatically diluted.
Analytical method
A new and previously validated method was used for the control of low volume cytotoxic preparations and, by extension, for all preparations in infusion bags and syringes [15] . Low volume preparations are defined as preparations with a final volume between 20 and 50 ml.
Preparations with a final volume of less than 20 ml are not analytically controlled. These preparations were also controlled by weighing and photography. The sample volume was modified to 1.0 ml, versus 1.2 ml initially. The analysis volume was 900 µl. Low volume preparations were overfilled with 1 ml of solvent, to ensure a match between the final volume and the labeling. The fraction of the total dose dedicated to the control is, at most 4.76% for preparations with a final volume of 20 ml. For all drugs, the analytical method was validated according to the ICH guidelines [19] .
Routine analysis
Quality controls were made on preparations destined to patients from August 2014 to December 2015. The QCPrep + ® automatically sends the results of each analysis in an Excel ® table, previously filled with the expected drug, solvent and final volume. The final volume of the preparations take into account the overfilling of the lowvolume preparations with 1 ml of solvent, the overfilling of infusion bags (dependent on the manufacturer), and the dead volume contained in the IV tube (if applicable).
The conformity or the NC of the sample is automatically determined, in relation to the predefined acceptance limits: ± 15% of the target concentration and a minimum of drug's recognition of 96%. The QCPrep + ® can automatically perform dilutions. Methotrexate calibration range is validated up to 5 mg/ml. Any preparation with a concentration greater than 5 mg/ml is diluted with sufficient factor to obtain a concentration analyzed in the range linearity domain. In case of NC, the preparations made in infusion bag with a volume greater than 50 ml are sampled again. The preparations in a syringe or infusion bag with a volume less than 50 ml are destroyed and remanufactured.
Indicators and analysis of results
Data was analyzed with Excel ® software. The main indicators were: the number of controls, the proportion of production analytically controlled and the conformity rates.
For the number of controls, results were sorted by type of preparation ("low volume" or "high volume"), by drug and by month. "Low volume" preparations corresponded to syringe or infusion bag preparations with a final volume less than 50 ml. "High volume" preparations correspond to infusion bag with a final volume greater than 50 ml.
For conformity rates results were sorted by type of preparation (low volume or high volume) by drug (are distinguished the ready-to-use drugs from those requiring reconstitution), by month and by manipulator. The results distribution of validated preparations was analyzed using box-plot and dispersion graphs.
Results
General conformity and number of controls
From August 2014 to December 2015, 8,604 preparations have been made and 7,548 controls were carried out, including 5,481 in 2015. 87.7% (7,548/8,604) of production was analytically controlled versus 30% before the development of analytical control in 2013. Among these controls, 94.4% were conform (7,125/7,548) . The global conformity rate of high volume preparations (96.5% (1,784/1,849)) is significantly greater than that of low volume preparations (93.7% (5,341/5,699)) (p < 0.01) (table 1). The non-conformity rate for ready-to-use drugs was 6.2% (352/5652) versus 3.6% (68/1890) for drugs requiring reconstitution. The difference between these two rates is significant (p < 0.01).
Conformity by drugs
The eleven most manipulated cytotoxic drugs were asparaginase, cyclophosphamide, cytarabine, daunorubicin, doxorubicin, etoposide (base and phosphate), ifosfamide, methotrexate, vinblastine and vincristine Figure 2 ). Nine drugs have a conformity rate below 95%, and non-conformity rate better than 5% (cisplatin, decitabine, epirubicin, etoposide phosphate, methotrexate and all vinca alkaloids) ( Figure 2 ). Only 4 preparations of epirubicin and 9 of decitabine were controlled. However, among the most manipulated drugs, some have a conformity rate among the lowest: methotrexate (92.3%), vinca alkaloids (91.9%) and vincristine (90.6%) ( Figure 2 ). All analyzed concentrations were greater than the limit of quantification (LOQ) of the validated methods. 
Distribution of conform results
The distribution of conform results is represented with box plot ( Figure 3) . A "box" corresponds to the first and third quartile: it contains 50% of the positive control. The remaining 50% are present outside the box. Each whiskers covers approximately 2,7σ or 1.5xIQR (InterQuartile Range). The space between the two whiskers covers approximately 99.3% of the sample and allows to highlight potential outliers [20] . The more boxes are narrow, the more results are homogenous. The stroke in the middle of the box is the median. An ideal representation must have a narrow box, centered on 0 and have the smaller extremes. The majority of conform preparations of cytarabine are greater than 0%. Conformity rates for doxorubicin, ifosfamide, vinblastine, asparaginase, etoposide phosphate and vindesine are slightly less, but close, than 0%. The dispersion is narrow (narrow box) for doxorubicin, ifosfamide and etoposide phosphate and more important (wide box) for vinblastine, asparaginase and vindesine, a sign of a poorer homogeneity of the results. The profiles of cyclophosphamide, daunorubicin and vincristine are distributed close to -2.5% with fairly wide boxes. The conformity rates of methotrexate and etoposide are largely off-center 0% with low homogeneity. The points represent the outliers. Analysis of the concentrations (data not shown) of these preparations do not show correlation with low analytical sensitivity which may reveal falsely conform preparations. The acceptance limit was set at ± 15%. Taking into account an acceptance limit of ± 10% [10] , 86.3% of the preparations are still conform ( Figure 4) 
Dispersion of results
The dispersion of the results (conform or not) is shown in Figures 5, 6 , 7, 8, 9 and 10. Green dots represents conform preparations and red dots non-conform preparations. Several profiles stand out. Daunorubicin, doxorubicin and ifosfamide showed a homogeneous distribution of error depending on the concentration ( Figure 5 ). For asparaginase, cyclophosphamide, cytarabine and vinblastine and vindesine, the controls are rather carried out in the low area of calibrations range and the majority of NC are in this area too ( Figure 6 ) ( < 150.00 UI/ml for asparaginase, < 5.00 mg/ml for cytarabine and cyclophosphamide, < 0.30 mg/ml for vinblastine and < 0.10 mg/ml for vindesine). For vincristine, NC are distributed throughout the calibration range ( Figure 7 ). For etoposide, a positive drift is observed with increasing concentration (Figure 8 ). For etoposide phosphate, all of NC are below than -15% (Figure 8 ). Finally, for methotrexate, two profiles were observed depending on the concentrations. Calibration range is validated from 0 to 5 mg/ml. Preparations with final concentrations greater than 5 mg/ml require a dilution. For low concentrations ( < 5 mg/ml) the vast majority of NC were greater than 15% of theoretical concentration. For higher concentrations ( > 5 mg/ml) and requiring dilution, NC were all less than 15%. The number of NC does not vary with dilution factor. 
Conformity by manipulators
The results of conformity rate by manipulator are presented in Table 2 and in Figure 10 . The manipulator traceability's was not performed for 100 controls. The number of preparations made by each manipulator varied significantly: from 39 to 1523 preparations over the period. There is a significant proportion of NC given to the manipulator #8. This manipulator is the one who made the most preparations over the period. The results did not correlate with the activity (Figure 10 ): the best and worst conformity rates were obtained by the two manipulators who made least preparations. The manipulator who made most preparations has a conformity rate below 95%. For the majority of drugs, there is a homogeneous distribution of the NC according to the manipulator (Figure 11 ). Figure 4 : Distribution of conformity: less than ± 10% (green) and within ± 10% and ± 15% (orange). However one manipulator (number 8) generates the majority of NC for etopside phosphate (85%). He is also responsible for 37% of NC for cytarabine, 35% for asparaginase and 26% for vincristine.
Conformity after second control
In case of NC, a second analysis was usually performed for high volume preparations ( > 50 ml). For low volume preparations ( < 50 ml), a second sampling is not possible. Over the period, 52 high volume preparations were sampled a second time, corresponding to 80% of NC (52/65). 90.4% of these second controls were conform (47/52). Despite the destruction, 98 low volume preparations were sampled a second time, to investigate the cause of non-conformity. 77.6% of these preparations (76/98) were conform.
Discussion
Since the last decade, the analytical control of chemotherapy preparations has expanded significantly. In this aim, UV spectrometry coupled with Raman spectroscopy offers good performance to identify and quantify drugs. In our centralized unit, the pediatric preparations of chemotherapy are mainly made in syringes (60% of production) with a final volume less than 50 ml. The doses and concentrations are lower than in adults. A new assay method was developed and validated to enable the control of low volume preparations [15] . It is based on a modification of the sample and analysis volumes. Initially, a sample of 1.2 ml was taken and the analysis was performed with 1 ml of this sample. We have reduced the analysis volume to 900 µl and the sample volume to 1 ml. Low volume preparations are, beforehand, filled with 1 ml of additional solvent. This addition provides, after sampling, a final volume corresponding to the labelling. The dilution produced by the addition of 1 ml of solvent is negligible, for the drugs and concentrations controlled. The overtime, induced by the addition of solvent, is also negligible. The fractions of the total dose, dedicated to the control, were 4.76% for preparations of 20 ml and 1.96% for those of 50 ml. The preparations of less than 20 ml were not analytically controlled because their very low final volume and the large analysis volume, do not allow an analytical control with an automaton. The main disadvantage of this method is the impossibility to take a second sample for low volume preparations. In case of NC, preparations are destroyed and refabricated. Preparations which cannot be controlled by an analytical method are still controlled by a weighing system and a photographing system of the manufacturing steps. The overall conformity rate was 94.4% or 5.6% of NC. This result, corresponding to an implementation of the [11, 22] .
The first tests with the new method were carried out from April 2014. The conformity rate was 83.2%, after the implementation. The mastery of this new method lasted about 4 months with a team which was not dedicated to this activity. The absence of a second control tends to reduce the overall conformity rate and increase the number of destroyed preparations. Fifty-two high-volume preparations were sampled a second time, representing 80% of high-volume preparations non-conformities. 90.4% of these second controls were conform (47/52). Low volume preparations cannot be resampled. In order to determine whether the NC were true or false, 98 low-volume preparations were sampled a second time before destruction. 77.6% of these preparations (76/98) were conform. By extrapolation, we can estimate that approximately 275 of 358 low volume preparations NC have been destroyed while they were perhaps consistent but poorly homogenized. Although these results are hypothetical, we can estimate a conformity rate of 98.0% (7,400/7,548) for a second sample of low-volume preparations. It could be interesting to assess the financial cost of this impossibility of achieving a second sample. Excluding NC due to the assay method (low analytical sensitivity for small concentrations), false NC is usually due to poor homogenization as also noticed by Castagne et al. [22] where 92.2% of second control was conform after shaking. The bad homogenization of preparations is especially important because it generates a significant loss of time. The preparations are not stored inside safety cabinets, a second sample requires a new sterilization cycle, a sampling and analysis. This new cycle delays the preparation availability of several tens of minutes.
The need for reconstitution does not seem to affect the conformity of the preparations. Theoretically, the reconstitution step adds a risk of error. In practice, lower conformity rates for lyophilisate are not observed. However, the drugs and analytical performances are different and the results cannot be strictly compared.
The analysis of the results by type of molecule allowed us to highlight 9 drugs with a conformity rate below 95%: cisplatin, decitabine, epirubicin, etoposide phosphate, methotrexate and 4 vinca-alkaloids: vindesine, vinblastine, vincristine and vinorelbine (Figure 2 ). For cisplatin, epirubicin and decitabine, a small number of preparations have been completed and the impossibility of achieving a second sample tends to bias the results. For etoposide phosphate, the most of NC corresponds to a human factor ( Figure 11 ) and can be improved by training. The four vinca-alkaloids have similar structures which are difficult to discriminate. In addition, these molecules emit very weakly in Raman, and identification is performed in UV. The informativeness of UV spectrometry is low, the identification of vinca-alkaloids is therefore more difficult than for drugs emitting in Raman. The study of the conformity rate distribution (Figures 5, 6, 7, 8 and 9 ) shows multiple profiles. Several characteristics can be noted: the average error which, ideally, should be centered on 0%. Symmetry is observed for doxorubicin and ifosfamide and significant drift for etoposide and methotrexate. The second characteristic is the dispersion of the results, observed on the boxplot and on the graphs 6 to 9. The larger the boxes, the larger the clouds points, the less controls are homogeneous. Outliers represented on the boxplot correspond to results to be verified. In theory these results are too far from the rest of the sample population and need to be analyzed before being considered abnormal. In practice, they do not correspond to abnormal values but to approximations during preparation. An important dispersion is observed for asparaginase, cytarabine, cyclophosphamide, methotrexate and vinca-alkaloids (vindesine, vinblastine, and vincristine). This dispersion is not related to the extent of the calibration range (important for asparaginase and narrow for vincristine). A large dispersion is related to a greater number of NC. For drugs such as daunorubicin, doxorubicin and ifosfamide, low dispersion is accompanied by a limited number of NC. The last point is the concentrations areas of NC. NC are concentrated in the low area of calibration range for asparaginase, cyclophosphamide, cytarabine, daunorubicin and doxorubicin, vinblastine and vindesine. Asparaginase is an enzyme prescribed in IU. The UV/Raman assay does not measure enzymatic activity, but may vary depending on the batches. A new calibration range has not been developed for each new batch. However, NC do not appear to be linked to batches. The conformity rate is stable and does not decrease over time, NC are isolated which does not evoke a batch effect. NC are concentration independent for ifosfamide, vincristine, etoposide, etoposide phosphate and methotrexate. These results show that low concentrations of pediatric preparations tend to increase the number of NC. Two drugs have a particular profile: vincristine and methotrexate. Vincristine is a preparation made in a dilution bag [23] in a fixed volume of 20 ml. The results show a significant number of NC over the entire range. A simulation using methylene blue, diluted in a 20 ml and 50 ml G5% infusion bag, revealed two critical points: the small volume makes difficult the homogenization of the preparation and the infusion tubing volume comprised between the sampling site and the contents of the bag must be imperatively homogenized before sampling. This simulation had led us to optimize our procedure of homogenization by 5 complete turns of the bag and 5 back and forth of with the sampling syringe.
The concentrations of methotrexate preparations are ranged from 0.7 to 100 mg/ml and the calibration range is validated from 0 to 5 mg/ml. Preparations with a concentration greater than 5 mg/ml are therefore diluted before analysis. Without dilution, NC are in the low area of the range and overestimate. Conform results are distributed homogeneously around 0%. After dilution, NC are not dependent on the dilution factor. All results (conform and non-conform) tend to be underestimated. These results show that in the absence of dilution, NC follow the trend of other drugs: low pediatric concentrations increase the number of NC. The dilution performed automatically by QCPrep + ® shows a tendency, for methotrexate, to underestimate the results. The effectiveness of the dilution system has been evaluated indirectly during the method validation. In case of dilution failure during the realization of the range, the quality controls would not be conformed. The QCPrep® has shown its limits for low concentrations. This weakness was evoked by Bazin et al. in their comparison of the various analytical tools available for the control of chemotherapy [6] . This observation correlates with our conformity results which are less good than those observed in adults [16, 21] . The majority of our NC can be attributed to the lack of analytical sensitivity in low concentration areas. It is particularly found for the small concentrations of vinca alkaloids (e.g. for vincristine doses less than 1 mg), cytarabine, methotrexate, arsenic (for which the calibration range could not be validated). This problematic tends to increase the number of NC and represents an important limit of the analytical control of pediatric preparations. In practice, the implementation of an analytical method for the control of pediatric preparations represents an important improvement for a safe preparation circuit. However, it must be complemented by another method of control like photography system (voice-activated camera), or video [9] . It allows to carry out a double control in case of doubt and allows to control the preparations with very low concentration.
We have set, as many units and authors [11, 16, 21] , the validation criteria to ± 15%. Yet, the majority of controls matched the ± 10% range (Figure 4) . 86.2% of controls were between 0% and ± 10% (Figure 4 ) against 93.0% for Nardella et al. [16] and 95.4% for Dziopa et al. [21] . The detailed results showed that the number of controls between ]-15%; -10%] and ]+10%; + 15%] is more important for etoposide, methotrexate, vincristine, and vindesine. For these four drugs, the problems (analytical sensitivity, dilution, and homogenization) are identified. The French society of oncology pharmacy (SFPO) recommends setting the validation criteria to ± 10% [10] . The establishment of this validation criterion would increase our number of NC and a significant number of methotrexate, vinca alkaloid and etoposide preparations would be destroyed. We can assume that a certain number of these preparations are not homogeneous. In case of a second sample, a significant number of these preparations would have a percentage error below 10%. Thus, the SFPO recommendation cannot yet be applied.
The study of manipulator conformity rate is interesting and, to our knowledge, rarely realized. The number of preparations made by each manipulator varies significantly: from 39 to 1523 preparations over the period. This difference is explained by the unit organization. Indeed, there is no pharmacy technicians dedicated to the activity; each of them rotates weekly. Depending on schedules, manipulators work in the production unit once every two weeks to once every 5 weeks. However, the conformity rate reported to the activity shows that, except the manipulator who made most preparations, the conformity rate increased with activity. Three less good conformity rates were observed for the manipulators who made least preparations. Surprisingly, the best conformity rate is also observed for manipulators having made the least preparations. In our case, this is explained by the fact that these manipulators have more experience in handling cytotoxic. The pharmacy technician who made most preparations, 20% of the activity, has the third worst conformity rate. We observed that he was the source of the vast majority of NC for etoposide phosphate (85%) and more than 25% of NC for vincristine, cytarabine and asparaginase. Studying NC by manipulator has permitted us to adapt the staff training. We set up individual training sessions focused on the shortcomings of each manipulator.
Conclusion
Securing the circuit of the cytotoxic drugs is a major issue to improve the safety of patients [24] . The analytical control is a reliable and effective method to ensure the quality of chemotherapy preparations. The development of an analytical method suitable for low volume preparations, allows young patients to benefit the same level of safety and quality that adult patients. Studying conformity results from our unit allowed us to highlight the improvement points. The main drawback of the assay method developed is reflected on the NC results. A significant number of preparations are destroyed without being rechecked. In order to improve our results, improved calibration ranges is in progress in order to reduce the drifts observed with some drugs. The establishment of the manipulator monitoring by conformity rate is a good indicator to highlight discrepancies inherent to the staff. These results allowed us to personalize our training to improve the quality of chemotherapy circuit.
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